D C Talbot
Overview
Explore the profile of D C Talbot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
896
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Basu B, Krebs M, Sundar R, Wilson R, Spicer J, Jones R, et al.
Ann Oncol
. 2018 Jul;
29(9):1918-1925.
PMID: 30016392
Background: We have previously shown that raised p-S6K levels correlate with resistance to chemotherapy in ovarian cancer. We hypothesised that inhibiting p-S6K signalling with the dual m-TORC1/2 inhibitor in patients...
2.
Khan O, Blann A, Payne M, Middleton M, Protheroe A, Talbot D, et al.
Br J Cancer
. 2011 May;
104(12):1822-7.
PMID: 21587257
Background: Combined therapy of metronomic cyclophosphamide, methotrexate and high-dose celecoxib targeting angiogenesis was used in a phase II trial. Methods: Patients with advanced cancer received oral cyclophosphamide 50 mg o.d.,...
3.
Catt S, Langridge C, Fallowfield L, Talbot D, Jenkins V
Eur J Cancer
. 2011 Apr;
47(10):1490-7.
PMID: 21454072
Background: Communication with patients contemplating Phase 1 cancer trial participation can be challenging. Controversy exists as to whether they are provided with sufficient information to give genuinely informed consent. We...
4.
Medley L, Morel A, Farrugia D, Reed N, Hayward N, Davies J, et al.
Br J Cancer
. 2011 Mar;
104(7):1067-70.
PMID: 21386841
Background: This study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic non-pancreatic neuroendocrine tumours (NETs). Methods: Multicentre phase II, first-line study...
5.
Deplanque G, Madhusudan S, Jones P, Wellmann S, Christodoulos K, Talbot D, et al.
Br J Cancer
. 2004 Sep;
91(9):1645-50.
PMID: 15354209
IM862 is a naturally occurring dipeptide (L-glu-L-trp) with immunomodulatory and antiangiogenic properties. A significant anticancer activity has been reported recently in AIDS-related Kaposi's sarcoma, a tumour of endothelial cell origin....
6.
Jones P, Christodoulos K, Dobbs N, Thavasu P, Balkwill F, Blann A, et al.
Br J Cancer
. 2004 May;
91(1):30-6.
PMID: 15162145
Marimastat, low molecular weight heparins and captopril have antiangiogenic activity in vitro and in animal models. We studied the safety and efficacy of the combination of these drugs in patients...
7.
Wall L, Talbot D, Bradbury P, Jodrell D
Br J Cancer
. 2004 Feb;
90(4):800-4.
PMID: 14970856
BB-3644 is an oral, broad-spectrum matrix metalloproteinase inhibitor (MMPI) structurally related to marimastat and BB-94. It is also >10-fold more active than marimastat in inhibiting the processing of cell-bound TNF-alpha....
8.
Han C, Braybrooke J, Deplanque G, Taylor M, Mackintosh D, Kaur K, et al.
Br J Cancer
. 2003 Oct;
89(7):1166-71.
PMID: 14520440
The aims of this study were to identify prognostic variables for toxicity and survival in patients with cancer participating in phase I clinical trials and compare characteristics of those treated...
9.
Jones P, Burnett R, Fainaru I, Nadolny P, Walker P, Yu Z, et al.
Br J Cancer
. 2003 Aug;
89(5):808-15.
PMID: 12942109
Tazarotene is an acetylenic retinoid which is metabolised to tazarotenic acid and which binds selectively to the retinoid receptors RARbeta and RARgamma. The safety, toxicity and pharmacokinetics of oral tazarotene...
10.
Braybrooke J, Ranson M, Manegold C, Mattson K, Thatcher N, Cheverton P, et al.
Lung Cancer
. 2003 Jul;
41(2):215-9.
PMID: 12871785
Background: Exatecan mesylate (DX-8951f) is a water soluble analogue of camptothecin that inhibits topoisomerase I. This multi-centre phase II study evaluated the activity of single agent exatecan in previously untreated...